PTC Therapeutics

– Preclinical and early research gene therapy programs discontinued –– Expected reductions of approximately 15% in residual 2023 OPEX – SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. PTC will continue … Read more

– Conference call and webcast to be held at 5:00 pm EDT –  SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia. The study did not meet its primary endpoint of statistically significant change in mFARS score … Read more